Vemircopan is a small molecule commercialized by AstraZeneca, with a leading Phase II program in IgA Nephropathy (Berger’s Disease). According to Globaldata, it is involved in 15 clinical trials, of which 11 were completed, 2 are ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Vemircopan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The revenue for Vemircopan is expected to reach an annual total of $14 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Vemircopan Overview

Vemircopan (ALXN-2050) is under development for the treatment of component 3 glomerulopathy (C3G /membranoproliferative glomerulonephritis Type II / dense deposit disease). It is administered through oral route. The drug candidate acts by targeting complement factor D. It was also under development for paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG).

AstraZeneca Overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$45,811 million for the fiscal year ended December 2023 (FY2023), an increase of 3.3% over FY2022. In FY2023, the company’s operating margin was 17.9%, compared to an operating margin of 8.5% in FY2022. In FY2023, the company recorded a net margin of 13%, compared to a net margin of 7.4% in FY2022. The company reported revenues of US$12,938 million for the second quarter ended June 2024, an increase of 2% over the previous quarter.

For a complete picture of Vemircopan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.